ENIOI/Monarsen

The success of ENIOI/Monarsen treatment in animal models led recently to clinical trials in human myasthenic patients, which are simultaneously run in Israel and the UK. ENIOI/Monarsen is provided at a daily single orally delivered dose followed by measurable improvement in muscle functioning (Argov et al, 2007). The reported effect lasts over 24 h, with a 100-fold lower required molar dose than that of pyridostigmine. 

AChE-R overexpression in myasthenic muscles, and perhaps explaining their short-lasting effect. In contrast, ENIOI/Monarsen should not activate this feedback loop, providing yet another added value to its use. 

---